Experimental compound could be used to treat pancreatic cancer
Using a compound called PTC596 in combination with other drugs, researchers effectively treated pancreatic cancer in mice.
List view / Grid view
Using a compound called PTC596 in combination with other drugs, researchers effectively treated pancreatic cancer in mice.
A chaperone protein has been identified as a possible therapeutic target for the treatment of Kennedy's disease and prostate cancer.
Researchers have identified a pathway in the immune system activated in Crohn's disease which could lead to investigating new treatments.
A study has found that signals from interferons can be blocked, allowing the immune system to attack tumours which provides a potential target.
A research team have used genome editing to correct two of the mutations that cause cystic fibrosis.
The ISCT is objecting linking the benefits of cellular immunotherapy with third party offerings of T-cell banking for future therapeutics.
A novel nano-vaccine has been developed which has proven effective in treating primary tumours and metastases that result from melanoma.
A new drug called IP1867B, which could be used for future treatments of brain tumours, is being examined.
The first genetically modified mini human livers have been grown in a laboratory, to emulate liver disease progression and test therapeutics.
A combination of heart cells derived from human stem cells could lead to developing a treatment for heart failure.
Researchers hope the system can choose the right patients to enroll in clinical trials, to speed discovery of drug treatments.
A new mouse model, called 'wildlings', has been developed which better mirrors human immune responses than standard laboratory mice.
A new experiment has not only slowed the progression of the prion disease, scrapie, it also extended the lives of prion-infected mice
It has been discovered that Polo-like kinase (PLK1) guards against severe DNA damage and could help target fast-growing cancer cells.
Researchers have discovered a subtype of immune cells that contribute to allergic reactions and anaphylaxis, providing a drug target.